17554 Holly Well Ave., Tampa, FL 33598
July 17, 2026 Medifast introduces a new program called Trilivy(TM), a science-backed metabolic health system. Trilivy replaces the former Optavia plan, that was focused only on weight loss. According to the press release: The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary […]
Medifast Launches Trilivy, Replaces Optavia Read More »
March 15, 2026 Medifast is an MLM (multilevel marketer) that sells meal replacements and diet foods, via health coaches. Their sales declined by 36% in 2025, to $386 million. Herbalife is another MLM that sells meal replacements and appetite suppressants, via health coaches. Their weight loss product sales in North America only declined by an
A Tale of Two MLM Competitors Read More »
March 4, 2026 Marketdata LLC has released a new report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast” This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts. Some findings: The total U.S. weight loss market
U.S. Weight Loss Market Now Worth $135 Billion – New Report Read More »
Feb. 18, 2026 Medifast reported full-year and Q4 2025 results on February 17, 2026. 2025 revenues came in at $386 million – a 36% decrease from $602 million in 2024. The company employed 16,100 active earning Optavia health coaches, who had quarterly earnings of $4,664 (or $18,656 on an annual rate). “As we enter 2026,
Medifast Reports Q4 and Full Year 2025 Results Read More »
February 18, 2026 Based on the latest press release and annual report by Herbalife… The North America region reported net sales of $1.03 billion for the year ended December 31, 2025, down 2.0%. Worldwide weight management product sales declined 0.8% in 2025. North American sales, at $1.03 billion, accounted for 20.5% of total Herbalife sales.
Herbalife’s Weight Loss Sales Remained Stable in 2025 Read More »
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number
Telehealth Companies Offer Novo’s Wegovy pill Read More »
Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for
Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »
Nov. 6, 2025 Weight loss products are a major part of Herbalife’s business, accounting for 55% of total sales for the first nine months of 2025. According to Stephan Gratziani, CEO,… “Herbalife’s third-quarter performance reflects continued progress in our transformation strategy, as well as disciplined financial and operational execution. With North America returning to growth
Herbalife Reports 3rd Qtr. Results Read More »
Oct. 15, 2025 A new Consumer Reports investigation has found that most protein powders and shakes — dietary supplements that have exploded in popularity in recent years — contain more lead in a single serving than is considered safe to ingest in an entire day. Technically, there’s no amount of lead that is considered safe
Study Finds high levels of lead in protein powders, shakes Read More »
Sept. 23, 2025 Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that provides a re-entry for the company into the market for obesity drugs. Pfizer on Monday said it will pay an initial $47.50 a share, or about $4.9 billion, for Metsera, a nearly 43% premium
Pfizer to Buy Weight-Loss Drug Developer Metsera Read More »